LOSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA LAB 50 mg/12.5 mg, film-coated tablet 28 tablets
Active ingredients: HYDROCHLOROTHIAZIDE, Losartan, Losartan potassium
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet28 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LOSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA LAB 50 mg/12,5 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC polyéthylène PVDC aluminium de 28 comprimé(s)
- Marketing authorisation holder
- ZENTIVA FRANCE
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 8 Apr 2020
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68040834CIP73014634CIP133400930146347Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| HYDROCHLOROTHIAZIDEcomprimé | 12,50 mg · un comprimé | SA |
| LOSARTAN POTASSIQUEcomprimé | 50 mg · un comprimé | SA |
| LOSARTANcomprimé | 45,76 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.